Teknova Reports First Quarter 2024 Financial Results
Alpha Teknova (Nasdaq: TKNO) released its Q1 2024 financial results, reporting a 2% increase in total revenue to $9.3 million compared to $9.1 million in Q1 2023. Lab Essentials revenue remained flat at $7.3 million, while Clinical Solutions revenue rose 7% to $1.7 million. The company launched the Build-Tek™ Solutions, an innovative product allowing quick buffer formulation for early-stage therapy development. Gross profit declined to $2.2 million due to increased overhead costs. Operating expenses dropped to $10.2 million, leading to a net loss reduction from $8.8 million in Q1 2023 to $8.1 million in Q1 2024. Adjusted EBITDA improved to negative $3.8 million from negative $6.1 million. Teknova reaffirmed its 2024 revenue guidance of $35-38 million and free cash outflow of less than $18 million.
- Total revenue increased by 2% to $9.3 million in Q1 2024.
- Clinical Solutions revenue grew 7% to $1.7 million.
- Teknova launched Build-Tek™ Solutions, enhancing early-stage therapy development.
- Operating expenses decreased to $10.2 million.
- Net loss reduced from $8.8 million in Q1 2023 to $8.1 million in Q1 2024.
- Adjusted EBITDA improved to negative $3.8 million from negative $6.1 million.
- Free Cash Flow improved to negative $6.7 million from negative $12.0 million.
- Reaffirmed 2024 revenue guidance of $35-38 million.
- Gross profit declined to $2.2 million from $2.4 million.
- Gross margin decreased to 23.8% from 26.6% due to increased overhead costs.
- Net loss for Q1 2024 was still significant at $8.1 million.
- Adjusted EBITDA remains negative at $3.8 million.
- Free Cash Flow remains negative at $6.7 million.
Insights
Teknova’s Q1 2024 financial results present a mixed picture for investors. Revenue increased by 2% to
On a positive note, operating expenses decreased by
In summary, while Teknova shows promising growth and prudent expense management, the narrowing margins and ongoing losses are areas that require close examination.
The introduction of the Build-Tek™ Custom Configurator and the AAV-Tek AAV Stabilizer indicates Teknova’s ongoing innovation in product development. The Build-Tek™ tool is designed to streamline the process for scientists, offering them multiple buffer formulations quickly. This innovation could significantly enhance efficiency in early-stage therapy development, enabling scientists to focus on core research tasks rather than buffer production, a tedious but necessary component of lab work.
The AAV-Tek AAV Stabilizer stands out due to its capability to increase capsid yield by up to 50% while maintaining product integrity. This is a significant enhancement for AAV purification workflows, which are critical in gene therapy research. High yield and product integrity are vital metrics in this field and the new stabilizer could give Teknova a competitive edge.
However, the true impact of these innovations will depend on market adoption and differentiation from existing solutions. Continued investment in R&D and fostering strong customer relationships will be key to leveraging these new products effectively in the market.
Teknova’s steady, albeit slow, growth in revenue and the launch of new products are signals of their strategic push in the biotech space. The company’s revenue from Lab Essentials remains flat, but Clinical Solutions revenue saw a 7% increase. This indicates growing demand for their clinical product offerings. The reaffirmation of their full-year outlook suggests confidence in continued growth, driven by both incremental advances in existing product lines and the introduction of new solutions like Build-Tek™ and the AAV-Tek Stabilizer.
Moreover, Teknova’s presence at the upcoming William Blair 44th Annual Growth Stock Conference can be a platform to attract new investors and build credibility within the investment community. The company’s strategic moves to manage operational costs, combined with prudent financial planning, reflect an awareness of the market dynamics and a focused approach to achieving sustainable growth.
First quarter 2024 total revenue was
Launch of Build-Tek™ Custom Configurator
Company reaffirms 2024 revenue guidance of
HOLLISTER, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2024.
“I am pleased with our performance in the first quarter,” said Stephen Gunstream, President and Chief Executive Officer at Teknova. “Not only did we deliver solid results, but we successfully introduced our latest product innovation – Build-Tek™ Solutions – developed specifically to enable scientists to receive multiple discrete buffer formulations in a matter of days for use during early-stage therapy development. We believe this first-of-its-kind, custom solution will enable our customers to focus on advancing science instead of spending their time on buffer production,” he added.
“During the first quarter of 2024, we delivered strong results overall and managed our operating expenses and capital expenditures to our plan. The combination of these results and improved order trends further strengthens our belief in our full-year outlook of
Corporate and Financial Updates
- First quarter 2024 total revenue of
$9.3 million , up2% from the first quarter 2023 - Launched Build-Tek Solutions, an online custom configurator that supports the fast turnaround of multiple, discrete buffer formulations for use during early-stage research and design of experiments (DOE)
- Introduced the latest product in our proprietary AAV-TekTM Solutions product line – the AAV-Tek AAV Stabilizer – a novel, multi-purpose solution that increases capsid yield up to
50% while safeguarding product integrity across the AAV purification workflow - Cash position of
$21.6 million and gross debt of$12.1 million at the end of the first quarter 2024
Revenue for the First Quarter
| For the Three Months Ended March 31, | |||||||
| (Dollars in thousands) | 2024 | 2023 | |||||
| Lab Essentials | $ | 7,266 | $ | 7,257 | |||
| Clinical Solutions | 1,718 | 1,609 | |||||
| Other | 306 | 255 | |||||
| Total revenue | $ | 9,290 | $ | 9,121 | |||
First Quarter 2024 Financial Results
Total revenue for the first quarter 2024 was
Gross profit for the first quarter 2024 was
Operating expenses for the first quarter 2024 were
Net loss for the first quarter 2024 was
Adjusted EBITDA for the first quarter 2024 was negative
Reiterates 2024 Outlook
Teknova is reiterating its fiscal 2024 outlook for revenue and free cash outflow. The Company continues to anticipate total revenue of
Upcoming Investor Conference Attendance
William Blair 44th Annual Growth Stock Conference
Chicago, Illinois, from
June 4 - 6, 2024
Conference Call and Webcast
Teknova will host a webcast and conference call on Monday, May 13, 2024, beginning at 5:00 p.m. ET. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to participate in the call, please register for the webcast here to receive a unique PIN number and dial-in information. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Teknova
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. Our fast turnaround of high-quality agar plates, microbial culture media, buffers, reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 200,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies.
Non-GAAP Financial Measures
This press release contains financial measures that have not been calculated in accordance with U.S. generally accepted accounting principles (GAAP). Teknova uses the following non-GAAP financial measures in assessing the performance of its business and the effectiveness of its business strategies: (a) Adjusted EBITDA and (b) Free Cash Flow.
Teknova defines Adjusted EBITDA as net loss adjusted for interest income (expense), net, provision for (benefit from) income taxes, depreciation expense, amortization of intangible assets, and stock-based compensation expense. Adjusted EBITDA reflects further adjustments to eliminate the impact of certain items, including certain non-cash and other items that Teknova does not consider representative of its ongoing operating performance.
Teknova defines Free Cash Flow as cash used in operating activities plus purchases of property, plant, and equipment.
Teknova provides Adjusted EBITDA and Free Cash Flow in this press release because Teknova believes that analysts, investors, and other interested parties frequently use these measures to evaluate companies in Teknova’s industry and that such measures facilitate comparisons on a consistent basis across reporting periods. Teknova also believes such measures are helpful in highlighting trends in Teknova’s operating results because they exclude items that are not indicative of Teknova’s core operating performance. Investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by Teknova may be different from the non-GAAP financial measures used by other companies.
A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release.
Forward-Looking Statements
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to Teknova’s anticipated total revenue, including our expectations for 2024 revenue and free cash outflow guidance, expected growth in Lab Essentials and Clinical Solutions, and other statements about Teknova’s business prospects, including about the Company’s profitability, strategy of managing operating expenses, and long-term growth strategy. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. These forward-looking statements are based on management’s current expectations and beliefs and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond Teknova’s control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, demand for Teknova’s products (including the potential delay to or pausing of customer orders); Teknova’s assessment of fundamental indicators of future demand across its target customer base; Teknova’s cash flows and revenue growth rate; Teknova’s supply chain, sourcing, manufacturing, and warehousing; inventory management; risks related to global economic and marketplace uncertainties, including those related to the conflicts in Ukraine and the Middle East; reliance on a limited number of customers for a high percentage of Teknova’s revenue; potential acquisitions and integration of other companies; and other factors discussed in the “Risk Factors” section of Teknova’s most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including in Teknova’s Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent Quarterly Reports on Form 10-Q filed with the SEC, all of which you may obtain for free on the SEC’s website at www.sec.gov. Although Teknova believes that the expectations reflected in its forward-looking statements are reasonable, Teknova does not know whether its expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by Teknova on its website or otherwise. Teknova does not undertake any obligation to update, amend, or clarify these forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.
Investor Contact
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100
Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
| ALPHA TEKNOVA, INC. Condensed Statements of Operations (Unaudited) (In thousands, except share and per share data) | ||||||||
| For the Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Revenue | $ | 9,290 | $ | 9,121 | ||||
| Cost of sales | 7,081 | 6,698 | ||||||
| Gross profit | 2,209 | 2,423 | ||||||
| Operating expenses: | ||||||||
| Research and development | 860 | 1,395 | ||||||
| Sales and marketing | 1,667 | 2,343 | ||||||
| General and administrative | 7,381 | 7,345 | ||||||
| Amortization of intangible assets | 287 | 286 | ||||||
| Total operating expenses | 10,195 | 11,369 | ||||||
| Loss from operations | (7,986 | ) | (8,946 | ) | ||||
| Other (expenses) income, net | ||||||||
| Interest (expense) income, net | (145 | ) | 93 | |||||
| Other income, net | — | 18 | ||||||
| Total other (expenses) income, net | (145 | ) | 111 | |||||
| Loss before income taxes | (8,131 | ) | (8,835 | ) | ||||
| Benefit from income taxes | (34 | ) | (18 | ) | ||||
| Net loss | $ | (8,097 | ) | $ | (8,817 | ) | ||
| Net loss per share—basic and diluted | $ | (0.20 | ) | $ | (0.31 | ) | ||
| Weighted average shares used in computing net loss per share—basic and diluted | 40,804,885 | 28,181,457 | ||||||
| ALPHA TEKNOVA, INC. Condensed Balance Sheets (Unaudited) (In thousands) | ||||||||
| As of March 31, | As of December 31, | |||||||
| 2024 | 2023 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 21,596 | $ | 28,484 | ||||
| Accounts receivable, net | 4,560 | 3,948 | ||||||
| Inventories, net | 11,207 | 11,594 | ||||||
| Prepaid expenses and other current assets | 1,460 | 1,634 | ||||||
| Total current assets | 38,823 | 45,660 | ||||||
| Property, plant, and equipment, net | 48,907 | 50,364 | ||||||
| Operating right-of-use lease assets | 17,400 | 16,472 | ||||||
| Intangible assets, net | 13,952 | 14,239 | ||||||
| Other non-current assets | 1,735 | 1,852 | ||||||
| Total assets | $ | 120,817 | $ | 128,587 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,543 | $ | 1,493 | ||||
| Accrued liabilities | 3,574 | 5,579 | ||||||
| Current portion of operating lease liabilities | 1,922 | 1,803 | ||||||
| Total current liabilities | 7,039 | 8,875 | ||||||
| Deferred tax liabilities | 884 | 919 | ||||||
| Other accrued liabilities | 78 | 102 | ||||||
| Long-term debt, net | 13,178 | 13,251 | ||||||
| Long-term operating lease liabilities | 16,260 | 15,404 | ||||||
| Total liabilities | 37,439 | 38,551 | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock | — | — | ||||||
| Common stock | — | — | ||||||
| Additional paid-in capital | 183,261 | 181,822 | ||||||
| Accumulated deficit | (99,883 | ) | (91,786 | ) | ||||
| Total stockholders’ equity | 83,378 | 90,036 | ||||||
| Total liabilities and stockholders’ equity | $ | 120,817 | $ | 128,587 | ||||
| ALPHA TEKNOVA, INC. Condensed Statements of Cash Flows (Unaudited) (In thousands) | ||||||||
| For the Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Operating activities: | ||||||||
| Net loss | $ | (8,097 | ) | $ | (8,817 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Bad debt expense | 7 | 2 | ||||||
| Inventory reserve | (91 | ) | (144 | ) | ||||
| Depreciation and amortization | 1,636 | 1,130 | ||||||
| Stock-based compensation | 1,307 | 1,010 | ||||||
| Deferred taxes | (35 | ) | (19 | ) | ||||
| Amortization of debt financing costs | 84 | 90 | ||||||
| Non-cash lease expense | 47 | 47 | ||||||
| Loss on disposal of property, plant, and equipment | 49 | — | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (619 | ) | (518 | ) | ||||
| Inventories | 478 | 240 | ||||||
| Prepaid expenses and other current assets | 174 | 271 | ||||||
| Other non-current assets | 117 | 102 | ||||||
| Accounts payable | 133 | (386 | ) | |||||
| Accrued liabilities | (1,724 | ) | (670 | ) | ||||
| Other | (24 | ) | (22 | ) | ||||
| Cash used in operating activities | (6,558 | ) | (7,684 | ) | ||||
| Investing activities: | ||||||||
| Proceeds from sale of property, plant, and equipment | 125 | — | ||||||
| Purchases of property, plant, and equipment | (112 | ) | (4,312 | ) | ||||
| Cash provided by (used in) investing activities | 13 | (4,312 | ) | |||||
| Financing activities: | ||||||||
| Proceeds from equity financing, net | (37 | ) | — | |||||
| Repayment of financed insurance premiums | (306 | ) | — | |||||
| Payment of at-the-market facility costs | — | (34 | ) | |||||
| Proceeds from exercise of stock options | — | 9 | ||||||
| Cash used in financing activities | (343 | ) | (25 | ) | ||||
| Change in cash and cash equivalents | (6,888 | ) | (12,021 | ) | ||||
| Cash and cash equivalents at beginning of period | 28,484 | 42,236 | ||||||
| Cash and cash equivalents at end of period | $ | 21,596 | $ | 30,215 | ||||
| ALPHA TEKNOVA, INC. Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures (Unaudited) (In thousands) | ||||||||
| For the Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Net loss – as reported | $ | (8,097 | ) | $ | (8,817 | ) | ||
| Add back: | ||||||||
| Interest (expense) income, net | (145 | ) | 93 | |||||
| Benefit from income taxes | (34 | ) | (18 | ) | ||||
| Depreciation expense | 1,349 | 844 | ||||||
| Amortization of intangible assets | 287 | 286 | ||||||
| EBITDA | $ | (6,350 | ) | $ | (7,798 | ) | ||
| Other and non-recurring expenses: | ||||||||
| Stock-based compensation expense | 1,307 | 1,010 | ||||||
| Severance pay and other termination benefits | 1,287 | 725 | ||||||
| Adjusted EBITDA | $ | (3,756 | ) | $ | (6,063 | ) | ||
| For the Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Cash used in operating activities | $ | (6,558 | ) | $ | (7,684 | ) | ||
| Purchases of property, plant, and equipment | (112 | ) | (4,312 | ) | ||||
| Free Cash Flow | $ | (6,670 | ) | $ | (11,996 | ) | ||
FAQ
What were Teknova's Q1 2024 total revenues?
How did Teknova's Lab Essentials revenue perform in Q1 2024?
What was Teknova's Clinical Solutions revenue in Q1 2024?
What is Teknova's 2024 revenue guidance?
What was Teknova's gross profit and margin in Q1 2024?
What was the net loss for Teknova in Q1 2024?
How did Teknova's operating expenses change in Q1 2024?
What is Teknova's free cash flow for Q1 2024?
What new product did Teknova launch in Q1 2024?
